| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc (ALKS) has 14 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. ALKS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 231.6K | $9.03M | - | |
| Dir | 135.9K | $5.30M | - | |
| VP | 90.4K | $3.52M | -9,000 | |
| CFO | 36.7K | $1.43M | - | |
| Dir | 35.8K | $1.40M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sale+OE | 1,938 | $34.00 | $65,892.00 | -20.1% | -11.9% | -12.3% | |
| Feb 25, 2025 | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sale+OE | 3,743 | $35.26 | $131,978.18 | -32.7% | -14.4% | -11.2% | |
| Feb 20, 2025 | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sale+OE | 1,327 | $35.69 | $47,360.63 | -14.7% | -14.0% | -10.1% | |
| Feb 13, 2025 | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sale+OE | 349,340 | $33.92 | $11,848,975.19 | -48.3% | -14.9% | -7.9% | |
| Jan 30, 2025 | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sale+OE | 100,918 | $32.05 | $3,234,381.53 | -69.5% | -9.8% | +6.2% | |
| Dec 9, 2024 | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sale+OE | 61,151 | $32.07 | $1,961,406.09 | -56.2% | +12.6% | -9.2% | |
| Dec 9, 2024 | Laurencin Cato T59 | Director | Sale+OE | 2,691 | $31.85 | $85,708.35 | -10.5% | +12.6% | -9.2% | |
| Dec 5, 2024 | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 9,221 | $31.50 | $290,461.50 | -13.4% | +13.1% | -5.4% | |
| Dec 4, 2024 | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 14,349 | $30.77 | $441,550.30 | -17.2% | +14.0% | -5.7% | |
| Nov 27, 2024 | Nichols Christian Todd51 | SVP, Chief Commercial Officer | Sell | 5,208 | $29.15 | $151,813.20 | -7.9% | +19.1% | +0.9% |